Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Ex Vivo Analysis of Organoid Culture

NCT04777604 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04777604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04777604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Ex Vivo Analysis of Organoid Culture
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2021
Completion date
January 7, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer